Restless legs syndrome (RLS), Parkinson's disease, and sustained dopaminergic therapy for RLS

Sleep Medicine

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Appiah Kubi, L S ^a   Pal, S ^a,b   Chaudhuri, K Ray ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dopaminergic therapy; Periodic leg movement; Restless legs syndrome

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; TALIPEXOLE;

ADULT; AGED; ARTICLE; CAREGIVER; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; REBOUND; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

EID: 0036863967     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-9457(02)00149-1     Document Type: Article

References (38)

1. Ekbom KA. Restless legs syndrome. Acta Med Scand 1945;158(Suppl):4-122.
2. Wills T. The London practice of physick. London: Basset and Crooke, 1685.
3. Symonds CP. Nocturnal myoclonus. J Neurol Neurosurg Psychiatry 1953;16:166-171.
4. Lugaresi E, Coccagna G, Tassinari CA, Ambrosetto C. Polygraphic data on motor phenomena in the restless legs syndrome. Riv Neurol 1965;35:550-561.
5. Walters AS. Toward a better definition of restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-642.
6. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002;58:341-346.
7. Chaudhuri KR, Appiah-Kubi L, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry 2001;71:143-146.
8. Eisenhsehr I, Wetter TC, Linke R, Noachtar S, et al. Normal IPT and IBZM SPECT in drug naÏve and levodopa treated idiopathic restless legs syndrome. Neurology 2001;57:1307-1309.
9. Staedt J, Stoppe G, Kogler A, Munz D, et al. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus). J Neural Transm Gen Sect 1993;93:71-74.
10. 11C-raclopride PET studies. Neurology 1999;52:932-937.
11. Ruottinen HM, Partinen M, Hublin C, Bergman J, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-504.
12. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999;14:141-145.
13. Silber M, Rye D. Solving the mysteries of narcolepsy: the hypocretin story. Neurology 2001;56:1616-1618.
14. Bara-Jimenez W, Aksu M, Sato GS, Hallett M. Periodic limb movements in sleep. State dependent excitability of the spinal flexor reflex. Neurology 2000;54:1609-1615.
15. Ondo WG, Vuong KD, Atassi F, Kwak C, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
16. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58:1019-1024.
17. Wetter TC, Collado-Seidel V, Pollmacher T, Yassourdis A, et al. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000;23:361-367.
18. Lees AJ, Blackburn NA, Campbell VL. The night-time problems of Parkinson's disease. Clin Neuropharmacol 1988;6:512-519.
19. Chaudhuri KR, Pal S, Bridgman K, Trenkwalder C. Achieving 24 hour control of Parkinson's disease symptoms: use of objective measures to improve nocturnal disability. Eur Neurol 2001;46(Suppl 1):3-10.
20. Pal S, DiMarco A, Pezzella F, Appiah-Kubi L, et al. Identification of a syndrome of nocturnal restlessness in Parkinson's disease using a novel visual analogue sleep scale (abstract). J Neurol Neurosurg Psychiatry 2002 (in press).
21. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991;31:41-43.
22. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
23. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
24. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-716.
25. Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998;51:1599-1602.
26. Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, et al. A randomised controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
27. Hening W, Allen R, Earley C, Kushida C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999;22:970-999.
28. Stiasny K, Wetter TC, Trenkwalder C, Oertel WH. Restless legs syndrome and its treatment by dopamine agonists. Parkinsonism Relat Disord 2000;7:21-25.
29. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow up study. Eur J Neurol 2000;7 (Suppl 1):27-31.
30. Stiasny K, Robbecke J, Schuler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline - an open clinical trial. Sleep 2000;23:349-354.
31. Chaudhuri KR, Clough C. Subcutaneous apomorphine in Parkinson's disease. Br Med J 1998;316:641.
32. Reuter I, Ellis CM, Chaudhuri KR. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999;100:163-167.
33. Chaudhuri KR, Bhattacharya KF, Agapito C, Porter MC, et al. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled release levodopa. Eur J Neurol 1999;6(Suppl): S11-S15.
34. Ghatani T, Agapito C, Bhattacharya K, Clough C, et al. Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal 'off' periods causing sleep disruption in Parkinson's disease. Eur J Neurol 2001;8(Suppl 1):8-11.
35. Ulm G, Schuler P, on behalf of the MODAC Study Group. Cabergoline versus pergolide a video-blinded, randomised, multicentre cross-over study. Aktuelle Neurol 1999;25:360-365.
36. Musch B. The long-acting dopamine agonist cabergoline in the treatment of early Parkinson's disease (abstract). 5th International Conference on Progress in Alzheimers, Kyoto, Japan, 2001. p. 117.
37. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 2000;15:664-668.
38. Appiah-Kubi L, Forbes A, Gunawardena D, Chaudhuri KR. The tolerability and efficacy of sustained dopaminergic therapy using cabergoline mono or adjunctive therapy in 202 elderly and young PD patients: a two year clinical observational study. Abstract P-MO-74 presented at the International Congress of Parkinson's Disease, Helsinki, Finland. Parkinsonism Relat Disord 2001;7:S28.